AI / data analytics / healthtech / informatics

#Academic #AI / data analytics / healthtech / informatics #Analysis #Cellular & Molecular biology #Chemistry #Clinical trials #Drug development #Drug discovery #Narrated podcasts

The COVID-19 Race: how mouse models will help researchers cross the finish line

The emergence of SARS-CoV-2 virus and the disease it causes, COVID-19, have fuelled significant shifts in preclinical research across the globe. Amid the worldwide health emergency created by high infection rates, rapid transmission spread and relatively high mortality rates, researchers are under pressure to understand the disease’s pathogenesis, develop… Read More

#Podcasts

#AI / data analytics / healthtech / informatics #Flow Cytometry

Automated flow cytometry analysis tools unlock pharma research insights

Tariq E. Khoyratty DPhil, Computational Biologist, Aigenpulse, and Satnam Surae PhD, Chief Product Officer, Aigenpulse, discuss the challenge of the large volume of data generated and how automation/AI/ML can help to manage this. As pharmaceutical companies expand their research and development (R&D) efforts to meet the growing global demand for new drugs,… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics

Rhythm AI receives MHRA approval for ROCSTAR clinical trial

Rhythm AI, a UK company focused on the treatment of Atrial Fibrillation (AF) has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to proceed with its multi-centre ROCSTAR clinical trial. This program will assess the company’s STAR Mapping System as a potential treatment for persistent AF. Read More

#News

#AI / data analytics / healthtech / informatics #Novartis

Stop, collaborate and listen: a model for successful pharma and vendor engagement

Digital transformations are having wide-ranging and profound impacts within life sciences, creating both opportunities and challenges. One of those challenges is adopting new software systems to drive the transformations. Pharma invests in powerful software technologies with the promise of increased efficiencies, but ultimately, if the interfaces are unintuitive and more… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Clinical trials #Covid-19

Sector professionals believe COVID-19 must trigger a change in clinical trials

As a consequence of the coronavirus pandemic, 41% of global clinical trials in fields other than COVID-19 (c.4,5001) have been delayed or put on permanent hold. Looking ahead, 74% of life science organisations say that COVID-19 will continue to compromise their ability to deliver on clinical trial objectives for the… Read More

#News

#AI / data analytics / healthtech / informatics #Alzheimer's #Biomarkers #iLoF

The start-up that knows one size doesn’t fit all

Luis Valente, CEO & Co-Founder of iLoF, has been recognized by Forbes as one of the top 30 under 30 for science and healthcare. He told Lu Rahman what’s behind his start-up that recently secured $1 million in investment from Microsoft’s Venture Fund, M12 and Mayfield Fund and won the… Read More

#Start-up Zone

#AI / data analytics / healthtech / informatics #Biopharma #Clinical trials #Covid-19 #Drug discovery #Therapeutics

Sitting down with…Biorelate

Daniel Jamieson is the CEO and Founder of Biorelate, a biomedical curation company that aims to accelerate insight and innovation in drug discovery. Lu Rahman spoke to him about his vision for the business, how COVID-19 has affected the landscape and the technology behind his drug discovery success. Biorelate was… Read More

#Opinion

#AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Regulatory

Automating regulatory data to drive discovery

The multi-year process of drug discovery and development creates huge silos of data and information. Extracting and combining information can be a significant overhead, resulting in potential for delay and error. Iperion’s Duncan van Rijsbergen provides practical recommendations to help companies create high quality, consistent data that may be shared… Read More

#Exclusive Content #Regulatory

#AI / data analytics / healthtech / informatics #Covid-19 #Drug candidates #Drug development #MS #Therapeutics

New for old: the value behind drug repurposing  

Lu Rahman looks at the drug repurposing market. How attractive a proposition is it financially?  More than ever the world is watching drug development and is aware of the time it takes to get a drug to market. The 10-15 years that this can involve is costly, so unsurprisingly, drug… Read More

#Covid-19 #Exclusive Content #Trends & Analysis

#AI / data analytics / healthtech / informatics #Pistoia Alliance

 Building foundations for post-COVID-19 R&D

Dr. Steve Arlington and Dr. Nick Lynch, The Pistoia Alliance, provide insight into pre-competitive collaboration and data sharing as we thinks about R&D beyond the pandemic  At the Pistoia Alliance, our mission is to encourage collaboration across the life sciences ecosystem. We believe that scientific advances and breakthroughs cannot be… Read More

#Business & Investment

#Academic #AI / data analytics / healthtech / informatics #Animal models #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug repositioning #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #PCR #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Race To COVID-19 cure – the Core Model for solving the pandemic crisis (Part 1 & 2)

By Ibis Sanchez-Serrano and Rathnam Chaguturu Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This article examines the major initiatives being explored at the public policy level to… Read More

#Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Chemistry #Clinical specialities #Clinical trials #Genetics / genomes #High Content Screening #Immunology / Virology & Vaccines #Pathology #Preclinical #Stem cells #Target validation #Therapeutics

The COVID-19 race: how mouse models will help researchers cross the finish line

THE COVID-19 RACE how mouse models will help researchers cross the finish line By Dr Megan MacBride The emergence of SARS-CoV-2 virus and the disease it causes, COVID-19, have fuelled significant shifts in preclinical research across the globe. Amid the worldwide health emergency created by high infection rates, rapid transmission… Read More

#Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Molecular medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

High content screening in action: a powerful tool to identify novel antivirals and vaccines

By Dr Karin Bottcher High content screening (HCS) has played a significant role in infectious disease research and drug discovery to date and can be a strong tool in the age of COVID-19 and beyond. With a focus on viral diseases, this article will describe how HCS has been used… Read More

#Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Animal models #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Immunology / Virology & Vaccines #Molecular medicine #Precision medicine #Preclinical #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics

New manufacturing technologies make the promise of stem cell therapies a reality

By Dr Ross Macdonald Cell-based therapies are being widely recognised for their potential to treat a variety of medical conditions, but they face major obstacles toward commercialisation. Traditionally, they have been difficult and expensive to make in large quantities. Biopharmaceutical companies must develop manufacturing solutions that will enable them to… Read More

#Business & Investment #Covid-19 #Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Cell therapy #Clinical trials #Drug development #Drug targets #Gene therapy #Immunology #Immunology / Virology & Vaccines #Molecular medicine #Oncology #Precision medicine #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Honing in on perfect targeting

Honing in on perfect targeting By Dr Samantha Zaroff Volume 21 Issue 3 - Summer 2020 The pros and cons of different delivery modalities for personalised cancer vaccines. Introducing neoantigens directly into a patient in order to elicit an anti-tumour killing immune response is known as personalised cancer vaccine therapy. Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Business #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #Genomics #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Organic chemistry #Pharmokinetics #Precision medicine #RNA #Screening #System biology #Systems biology #Therapeutics #Toxicology

The COVID-19 antiviral race: we’re all in this together

The COVID-19 antiviral race: we're all in this together By Uduak Grace Thomas In response to the COVID-19 pandemic, international scientists from academia and industry have pooled their expertise and resources to identify candidate compounds that inhibit the activity of the SARS-CoV-2 main protease, in order to develop a clinically… Read More

#Covid-19 #Exclusive Content